← All Pasithea Therapeutics CORP filings

Pasithea Therapeutics CORP DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
KTTA
Pasithea Therapeutics CORP
DEF: Pasithea Therapeutics Proposes Reverse Stock Split to Avoid Nasdaq Delisting
Pasithea Therapeutics Corp. is seeking stockholder approval for a reverse stock split, ranging from 1-for-2 to 1-for-20, to regain compliance with Nasdaq's minimum bid price requirement and avoid potential delisting.
NASDAQ
KTTA
Pasithea Therapeutics CORP
DEF: Pasithea Seeks Shareholder Approval for Major Stock Increase
Pasithea Therapeutics Corp. is calling a Special Meeting of Stockholders to vote on increasing authorized common stock by 400% and expanding its 2023 Stock Incentive Plan.
NASDAQ
KTTA
Pasithea Therapeutics CORP
DEF: Pasithea Therapeutics Seeks Shareholder Approval for Reverse Stock Split and Expanded Equity Plan to Maintain Nasdaq Listing
Pasithea Therapeutics Corp. will hold its Annual Meeting of Stockholders to vote on key proposals including a reverse stock split to address Nasdaq's minimum bid price requirement and an increase in authorized shares for its equity incentive plan.
NASDAQ
KTTA
Pasithea Therapeutics CORP
DEF 14A: Pasithea Therapeutics Sets Date for Virtual Annual Meeting, Seeks Stockholder Approval on Key Proposals
Pasithea Therapeutics will hold its annual stockholder meeting virtually on June 26, 2024, to vote on the election of a director and the ratification of its independent auditor.